Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.37 |
| ▸ | PRCP | P42785 | 2/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630716 | 0.96 | DPP7 (0.38) | DPP7MEN1KMT2ACTSCHDAC3 | |
| SCHEMBL31146508 | 0.91 | DPP7 (0.43) | DPP7MEN1KMT2ACTSCHDAC3 | |
| SCHEMBL31122253 | 0.89 | CALCRL (0.45) | DPP7MEN1KMT2ACTSCPRCP | |
| SCHEMBL29947749 | 0.88 | DPP7 (0.40) | DPP7MEN1KMT2ACTSCHDAC1 | |
| SCHEMBL30823909 | 0.86 | DPP7 (0.44) | DPP7MEN1KMT2ACTSCHDAC3 | |
| SCHEMBL29421982 | 0.86 | TERT (0.40) | MEN1KMT2APRCPGLO1PTGS1 | |
| SCHEMBL30910373 | 0.85 | KMT2A (0.46) | DPP7MEN1KMT2ACTSCPRCP | |
| SCHEMBL29630487 | 0.85 | KMT2A (0.46) | DPP7MEN1KMT2ACTSCPRCP | |
| SCHEMBL32678598 | 0.85 | KEAP1 (0.42) | TERT | |
| SCHEMBL32678599 | 0.85 | KEAP1 (0.42) | TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024571-B2 | Anti-erythropoietin receptor peptide | EPO-MED INC. (JP) | 2024-07-02 | — | — | US | disclosed |
| US-20230310539-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | EPO-MED INC. (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-3436012-B1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES INC (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-4190345-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | Epo-Med Inc. (JP) | 2023-06-07 | — | — | EP | disclosed |
| CN-116234541-A | Treatment of diseases by EpoR antagonists | EPO医药株式会社 | 2023-06-06 | — | — | CN | disclosed |
| WO-2022025204-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | エポメッド株式会社 | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024571-B2 | Anti-erythropoietin receptor peptide | EPOR, PRLHR, AVPR1A | DPP7 2344/4885MEN1 1632/4885KMT2A 1028/4885 |
| US-20230310539-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | EPOR, PROKR1, HBZ | DPP7 2567/4885MEN1 2223/4885KMT2A 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.